A PYMNTS Company

India: Gov’t shuns foreign pharma ownership, halts US buyout of Agila

By  |  July 8, 2013

India’s Foreign Investment Promotion Board deferred a ruling on a $1.6 billion planned buyout of Agila Specialties by US firm Mylan Inc., putting at least a temporary stop to a deal part of a larger trend of foreign ownership of India-based cancer drug companies. Reports say the Department of Industrial Policy and Promotion recently raised concerns that foreign takeovers of pharmaceutical companies is threatening the cancer drug and vaccine market. Government officials cited a 2009 deal that saw a French takeover of Hepatitis B vaccine maker Sanofi Aventis; the result of the deal was skyrocketed vaccine prices in the country. DIPP’s foreign investment board is looking to prevent another such situation through halting the recent buyout, which would be one of the largest in the pharmaceutical sector in recent years, say reports.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: Economic Times

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.